Inactive Instrument

Aquinox Pharmaceuticals Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
-	-

Mar. 22	North American Morning Briefing : Stocks Struggle After New Records	DJ
Mar. 21	William Blair Initiates Neurogene With Outperform Rating	MT

NEOLEUKIN THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)

August 03, 2020 at 05:13 pm EDT

Item 7.01 Regulation FD Disclosure

On August 3, 2020, Neoleukin Therapeutics, Inc., "Neoleukin" submitted a manuscript to bioRxiv, titled "De novo design of ACE2 protein decoys to neutralize SARS-CoV-2". BioRxiv is an online archive for unpublished preprints in the life sciences. The manuscript details the creation of a de novo protein decoy that binds to the SARS-CoV-2 spike protein and neutralizes viral infection of mammalian cells in vitro. The research was conducted by Neoleukin scientists and colleagues at the University of Hong Kong, University of Washington and University of North Carolina at Chapel Hill. The manuscript is currently undergoing peer review. Once posted, the manuscript will be available at bioRxiv.org.

--------------------------------------------------------------------------------

Latest news about Aquinox Pharmaceuticals Inc

North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
William Blair Initiates Neurogene With Outperform Rating	Mar. 21	MT
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04	CI
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	Feb. 21	CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	Jan. 17	CI
Neurogene Names Julie Jordan as Chief Medical Officer	Jan. 16	MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16	CI
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	Jan. 08	MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	Jan. 05	MT
Neurogene Announces Business Update and 2024 Outlook	Jan. 05	CI
Neurogene Completes Merger With Neoleukin Therapeutics	Dec. 19	MT
Neoleukin Therapeutics, Inc.(NasdaqCM:NLTX) dropped from NASDAQ Composite Index	Dec. 18	CI
Neurogene Inc. announced that it has received $95 million in funding from a group of investors	Dec. 17	CI
Neurogene Inc. completed the acquisition of Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $120 million in a reverse merger transaction.	Dec. 17	CI
Neoleukin Therapeutics Board Approves Reverse Stock Split, Increase in Authorized Common Stock Capital to 500 Million	Dec. 15	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sector Update: Health Care Stocks Rise Slightly Late Afternoon	23-09-22	MT
Sector Update: Health Care Stocks Mixed Friday Afternoon	23-09-22	MT
Neoleukin Therapeutics Board Approves 1-for-5 Reverse Stock Split	23-09-22	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Neoleukin Therapeutics, Inc., Neurogene Inc. - M&A Call	23-07-18
Neoleukin Therapeutics to Merge With Neurogene in All-Stock Deal	23-07-18	MT
Neurogene Inc. entered into a definitive merger agreement to acquire Neoleukin Therapeutics, Inc. in a reverse merger transaction.	23-07-17	CI

Chart Aquinox Pharmaceuticals Inc

Duration

Period

More charts

Company Profile

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The Company uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on key cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The Company operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The Company's primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.

Sector

Calendar

2024-05-09 - American Society of Gene & Cell Therapy Meeting - Poster No. 1408

More about the company